Effects of Montelukast treatment in asthmatic children under 5 years
Phase 3
- Conditions
- Asthma in children.AsthmaJ40?J47
- Registration Number
- IRCT201204099429N1
- Lead Sponsor
- Tabriz University of Medical Sciences, Assistance Research
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 68
Inclusion Criteria
(no abnormalities underlying anatomic disease? family history of allergies and asthma patient ) And exclusion criteria: (anatomical issues such as the children with Gastroesophageal Reflux Disease? Cystic fibrosis ? underlying medical condition such as cardiovascular problems they are not in the study).
Exclusion Criteria
Not provided
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Wheeze intensity. Timepoint: The severity of wheezing diagnosed based on clinical examination and recorded every 2-4 weeks to 6 months after starting treatment with Montelukast 5 mg daily and Fluticasone 100 mcg twice a day, patients are followed up. Method of measurement: Physical examination.
- Secondary Outcome Measures
Name Time Method Cough intensity. Timepoint: The severity of coughing diagnosed based on clinical examination and recorded every 2-4 weeks to 6 months after starting treatment with Montelukast 5 mg daily and Fluticasone 100 mcg twice a day, patients are followed up. Method of measurement: Physical examination.;Dyspnea intensity. Timepoint: The severity of dyspnea diagnosed based on clinical examination and recorded every 2-4 weeks to 6 months after starting treatment with Montelukast 5 mg daily and Fluticasone 100 mcg twice a day, patients are followed up. Method of measurement: Physical examination.